JP2006501298A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501298A5
JP2006501298A5 JP2004541124A JP2004541124A JP2006501298A5 JP 2006501298 A5 JP2006501298 A5 JP 2006501298A5 JP 2004541124 A JP2004541124 A JP 2004541124A JP 2004541124 A JP2004541124 A JP 2004541124A JP 2006501298 A5 JP2006501298 A5 JP 2006501298A5
Authority
JP
Japan
Prior art keywords
compound
rejection
pharmaceutical composition
composition
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004541124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501298A (ja
JP4667870B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/004993 external-priority patent/WO2004031129A2/en
Publication of JP2006501298A publication Critical patent/JP2006501298A/ja
Publication of JP2006501298A5 publication Critical patent/JP2006501298A5/ja
Application granted granted Critical
Publication of JP4667870B2 publication Critical patent/JP4667870B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004541124A 2002-10-03 2003-10-01 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物 Expired - Fee Related JP4667870B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41550802P 2002-10-03 2002-10-03
PCT/IB2003/004993 WO2004031129A2 (en) 2002-10-03 2003-10-01 Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection

Publications (3)

Publication Number Publication Date
JP2006501298A JP2006501298A (ja) 2006-01-12
JP2006501298A5 true JP2006501298A5 (https=) 2006-11-30
JP4667870B2 JP4667870B2 (ja) 2011-04-13

Family

ID=32069867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004541124A Expired - Fee Related JP4667870B2 (ja) 2002-10-03 2003-10-01 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物

Country Status (12)

Country Link
US (2) US7642290B2 (https=)
EP (1) EP1546088B1 (https=)
JP (1) JP4667870B2 (https=)
AU (2) AU2003274605A1 (https=)
CA (1) CA2500935C (https=)
CY (1) CY1116107T1 (https=)
DK (1) DK1546088T3 (https=)
ES (1) ES2535975T3 (https=)
IL (1) IL167631A (https=)
PT (1) PT1546088E (https=)
SI (1) SI1546088T1 (https=)
WO (1) WO2004031129A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546088B1 (en) 2002-10-03 2014-12-17 Novaremed Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Aids及び他のウイルス性疾患及びhiv関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
FR2892923B1 (fr) * 2005-11-08 2009-01-16 Engelhard Lyon Sa Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
EP2026775B1 (en) * 2006-05-09 2015-04-29 Novaremed Ltd. Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
CA2669104A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
EP2003118A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2014287A1 (de) * 2007-06-13 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Verwendung von Zimtsäurederivaten als Modulatoren des EP2-Rezeptors
US20090017004A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
EP2475361B1 (en) * 2009-09-09 2019-11-06 Novaremed Ltd. N-substituted benzenepropanamides for use in the treatment of pain and inflammation
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
GB201116335D0 (en) * 2011-09-21 2011-11-02 Novaremed Ltd A method of treating or preventing affective disorders
DK2788317T3 (da) 2011-12-08 2020-01-20 Novaremed Ltd Isolerede stereoisomere former af (S)2-N(3-O-((S)propan-2-ol)-1-propyl-4-hydroxybenzen)-3-phenylpropylamid
WO2015173813A1 (en) * 2014-05-14 2015-11-19 Novaremed Ltd. Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes
ES2578377B1 (es) 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.
WO2018053116A1 (en) 2016-09-14 2018-03-22 Invisalert Solutions, LLC Tamper resistant clasp and wristband apparatus and associated patient monitoring system and method of use
CA3087269A1 (en) 2018-01-10 2019-07-18 Brightseed, Inc. Method for modulating metabolism
US12017973B2 (en) 2018-06-22 2024-06-25 Basf Se Amino acid based surfactants as formulants for biocides
USD906359S1 (en) 2018-07-05 2020-12-29 Invisalert Solutions, Inc. Display screen with graphical user interface
CN113329746B (zh) 2019-01-23 2025-05-02 诺瓦麦有限公司 用于治疗或预防疼痛、炎症和/或自身免疫的化合物
CN114929033A (zh) * 2019-07-29 2022-08-19 布莱特西德公司 改善消化健康的方法
CA3153945A1 (en) 2019-09-11 2021-03-18 Invisalert Solutions, Inc. Wireless patient monitoring compliance system
US12315353B1 (en) 2024-06-04 2025-05-27 Invisalert Solutions, Inc. Patient safety monitoring method and apparatus
US12355745B1 (en) 2024-10-28 2025-07-08 Invisalert Solutions, Inc. Secure mobile device management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908691A (en) 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
JPS5236606A (en) * 1975-09-12 1977-03-22 Tanabe Seiyaku Co Ltd Process for preparation of amino compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4908322A (en) 1985-09-06 1990-03-13 The United States Of America As Represented By The Department Of Health And Human Services Derivatization of amines for electrochemical detection
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5566064A (en) 1995-05-26 1996-10-15 Apple Computer, Inc. High efficiency supply for electroluminescent panels
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
EP0887340A4 (en) 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
ID19116A (id) 1996-10-15 1998-06-18 Nippon Catalytic Chem Ind Bahan pengabsorpsi air dan proses produksinya
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2002046176A1 (en) 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Ppar (peroxisome proliferator activated receptor) activators
EP1546088B1 (en) 2002-10-03 2014-12-17 Novaremed Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Aids及び他のウイルス性疾患及びhiv関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
RU2309144C2 (ru) 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
EP2026775B1 (en) * 2006-05-09 2015-04-29 Novaremed Ltd. Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
AU2008302356A1 (en) 2007-09-17 2009-03-26 Academia Sinica Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus Amboinicus extracts
CN101503373B (zh) 2009-03-13 2013-07-24 山东大学 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2006501298A5 (https=)
IL167631A (en) Compounds and pharmaceutical compositions comprising same for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP2005525345A5 (https=)
JP2021515083A5 (https=)
JP2003508388A5 (https=)
JP2004522714A5 (https=)
JP2020512337A5 (https=)
RU2004133347A (ru) Лекарственное средство для профилактики и/или лечения хронического отторжения
JP2008508303A5 (https=)
JP2008543800A5 (https=)
JP2012508251A5 (https=)
JP2006512339A5 (https=)
JP2011516460A5 (https=)
JP2008506714A5 (https=)
JP2020500866A5 (https=)
RU2010103320A (ru) Противовоспалительная композиция
JP2006503805A5 (https=)
JPWO2019173539A5 (https=)
EP0227241A3 (en) Medicinal indole and indazole keto sulphone derivatives
JP2006516643A5 (https=)
JP2008509210A5 (https=)
JP2002534477A5 (https=)
JP2008543821A5 (https=)
JP2008521934A5 (https=)
RU2006117627A (ru) Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений